Skip to main content

Table 2 Characteristics of all mCRPC patients included in this study for Lu-177-PSMA-617 therapy

From: Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach

PSMA-617 P6 P7 P8 P9 P10
Age 68 66 61 47 73
Activity investigated cycle [MBq] 3718 3743 3745 3752 3700
Diagnosis mCRPC mCRPC mCRPC mCRPC mCRPC
Metastases (PET/CT)
 - Extend High High High High High
 - Type (VIS = visceral, LYM = lymph, OSS = osseous) Mainly VIS (liver), OSS, LYM Only OSS Mainly OSS, LYM Mainly OSS, LYM Mainly OSS, LYM
Initial TNM classification pT3b, pN1, R0, G3, Gleason 9 pT4, N1, R1, G3, Gleason 8 pT3b, pN1, R1, Gleason 9 pT3a, pN1, pR1, Gleason 9 pT4, N1, R1, Gleason 9
PSA [ng/ml] 368 1201 5436 408 101
Pre-therapies (1, yes/0, no)
 - Surgery 0 1 1 1 1
 - Radiotherapy 1 1 1 0 0
 - Anti-hormonal therapy (including bicalutamide, enzalutamide, abiraterone acetate) 1 1 1 1 1
 - Radionuclide therapy (Ra-223) 0 1 0 1 1
 - Chemotherapy (docetaxel, cabazitaxel) 1 1 1 1 0
Blood pre-therapy
 - Leukocytes [G/l] 4.90 7.20 5.60 6.20 5.00
 - Erythrocytes [T/l] 4.31 4.79 4.08 4.35 4.00
 - Thrombocytes [G/l] 307 195 291 314 191
 - Haematocrit 0.376 0.406 0.335 0.377 0.366